biospecimen__admin__batch_number	173.73.0
biospecimen__admin__bcr	Nationwide Children's Hospital
biospecimen__admin__day_of_dcc_upload	1
biospecimen__admin__disease_code	LIHC
biospecimen__admin__file_uuid	F3ECAF1B-F185-47E0-82E3-21F2A4D25857
biospecimen__admin__month_of_dcc_upload	7
biospecimen__admin__year_of_dcc_upload	2016
biospecimen__bio__bcr_analyte_barcode	TCGA-EP-A2KA-01A-11R
biospecimen__bio__bcr_portion_barcode	TCGA-EP-A2KA-01A-11
biospecimen__bio__bcr_sample_barcode	TCGA-EP-A2KA-01A
biospecimen__bio__biospecimen_barcode_bottom	0113416643
biospecimen__bio__day_of_creation	09
biospecimen__bio__day_of_shipment	31
biospecimen__bio__days_to_index	0
biospecimen__bio__gel_image_file	https://sharedoc.nchri.org/tcga-bcr/default.aspx
biospecimen__bio__is_derived_from_ffpe	NO
biospecimen__bio__month_of_creation	08
biospecimen__bio__month_of_shipment	08
biospecimen__bio__pathology_report_file_name	TCGA-EP-A2KA.CCEFF8C5-E949-4F3F-93DA-67ECF5503C1C.pdf
biospecimen__bio__plate_column	12
biospecimen__bio__plate_id	A17X
biospecimen__bio__plate_row	F
biospecimen__bio__portion_sequence	1
biospecimen__bio__quantity	3.20
biospecimen__bio__subportion_sequence	1
biospecimen__bio__vial_number	A
biospecimen__bio__volume	20.00
biospecimen__bio__year_of_creation	2011
biospecimen__bio__year_of_shipment	2011
biospecimen__shared__bcr_patient_barcode	TCGA-EP-A2KA
biospecimen__shared__patient_id	A2KA
clinical__admin__day_of_dcc_upload	22
clinical__admin__file_uuid	20731EE1-CC15-4F3E-8D83-125C9FAE55C7
clinical__admin__month_of_dcc_upload	12
clinical__admin__withdrawn	false
clinical__chol_lihc_shared__creatinine_upper_limit	1.0
clinical__chol_lihc_shared__creatinine_value_in_mg_dl	0.7
clinical__chol_lihc_shared__fetoprotein_outcome_lower_limit	0
clinical__chol_lihc_shared__fetoprotein_outcome_value	13
clinical__chol_lihc_shared__fibrosis_ishak_score	1,2 - Portal Fibrosis
clinical__chol_lihc_shared__hist_hepato_carc_fact	No History of Primary Risk Factors
clinical__chol_lihc_shared__platelet_result_lower_limit	140
clinical__chol_lihc_shared__platelet_result_upper_limit	415
clinical__chol_lihc_shared__specimen_collection_method_name	Lobectomy
clinical__clin_shared__age_at_initial_pathologic_diagnosis	52
clinical__clin_shared__bcr_followup_barcode	TCGA-EP-A2KA-F31967
clinical__clin_shared__bcr_followup_uuid	8A1E2B55-9C1A-476E-8FE2-A2CFF23FB7E2
clinical__clin_shared__cancer_first_degree_relative	2
clinical__clin_shared__day_of_form_completion	15
clinical__clin_shared__days_to_initial_pathologic_diagnosis	0
clinical__clin_shared__eastern_cancer_oncology_group	0
clinical__clin_shared__followup_case_report_form_submission_reason	Scheduled Follow-up Submission
clinical__clin_shared__informed_consent_verified	YES
clinical__clin_shared__lost_follow_up	NO
clinical__clin_shared__month_of_form_completion	5
clinical__clin_shared__person_neoplasm_cancer_status	WITH TUMOR
clinical__clin_shared__platelet_result_count	435
clinical__clin_shared__post_op_ablation_embolization_tx	NO
clinical__clin_shared__postoperative_rx_tx	NO
clinical__clin_shared__radiation_therapy	NO
clinical__clin_shared__relative_family_cancer_history	YES
clinical__clin_shared__residual_tumor	R0
clinical__clin_shared__tissue_prospective_collection_indicator	YES
clinical__clin_shared__tissue_retrospective_collection_indicator	NO
clinical__clin_shared__tumor_tissue_site	Liver
clinical__clin_shared__year_of_form_completion	2012
clinical__clin_shared__year_of_initial_pathologic_diagnosis	2011
clinical__lihc_nte__new_tumor_event_ablation_embo_tx	No
clinical__lihc_nte__new_tumor_event_liver_transplant	No
clinical__nte__additional_pharmaceutical_therapy	YES
clinical__nte__additional_radiation_therapy	NO
clinical__nte__days_to_new_tumor_event_after_initial_treatment	293
clinical__nte__new_neoplasm_event_occurrence_anatomic_site	Brain
clinical__nte__new_neoplasm_event_type	Extrahepatic Recurrence
clinical__nte__new_tumor_event_additional_surgery_procedure	NO
clinical__nte__new_tumor_event_after_initial_treatment	YES
clinical__rx__bcr_drug_barcode	TCGA-EP-A2KA-D31989
clinical__rx__bcr_drug_uuid	436550BB-A2DE-4EFA-A2F3-702BF8BAAEC5
clinical__rx__days_to_drug_therapy_start	312
clinical__rx__drug_name	Sorafenib
clinical__rx__therapy_ongoing	YES
clinical__rx__therapy_type	Targeted Molecular therapy
clinical__rx__tx_on_clinical_trial	NO
clinical__shared__histological_type	Hepatocellular Carcinoma
clinical__shared__history_of_neoadjuvant_treatment	No
clinical__shared__neoplasm_histologic_grade	G3
clinical__shared__other_dx	No
clinical__shared_stage__pathologic_m	MX
clinical__shared_stage__pathologic_n	NX
clinical__shared_stage__pathologic_t	T3a
clinical__shared_stage__system_version	7th
gdc__access	open
gdc__acl	open
gdc__aliquots__aliquot_id	c1e285f1-c1ba-4412-b0d8-3f82e0ed4cd4
gdc__aliquots__concentration	0.16
gdc__aliquots__source_center	23
gdc__aliquots__submitter_id	TCGA-EP-A2KA-01A-11R-A17X-13
gdc__aliquots__updated_datetime	2018-09-06T14:13:07.098771-05:00
gdc__analysis__analysis_id	64af98b5-5210-40f8-9c58-66f881466ef6
gdc__analysis__workflow_link	https://github.com/NCI-GDC/gdc-dnaseq-cwl/blob/gdc-active-submission/workflows/mirnaseq/runner.cwl
gdc__analysis__workflow_type	BCGSC miRNA Profiling
gdc__analytes__a260_a280_ratio	1.9
gdc__analytes__analyte_id	903c536b-7a01-4413-a29f-42a69d2d5251
gdc__analytes__analyte_type	RNA
gdc__analytes__analyte_type_id	R
gdc__analytes__spectrophotometer_method	UV Spec
gdc__case_id	440375d7-cdcd-418a-8992-0a8ca42d290d
gdc__center__center_id	6eba705a-0f00-5aa2-b1d0-04dbf62100cc
gdc__center__center_type	CGCC
gdc__center__code	13
gdc__center__name	Canada's Michael Smith Genome Sciences Centre
gdc__center__namespace	bcgsc.ca
gdc__center__short_name	BCGSC
gdc__created_datetime	2018-03-20T12:54:50.037061-05:00
gdc__data_category	Transcriptome Profiling
gdc__data_format	TXT
gdc__data_type	miRNA Expression Quantification
gdc__demographic__demographic_id	74dbb0d8-0b37-5650-8183-250643056c17
gdc__demographic__ethnicity	not hispanic or latino
gdc__demographic__gender	female
gdc__demographic__race	white
gdc__demographic__year_of_birth	1959
gdc__diagnoses__age_at_diagnosis	19214
gdc__diagnoses__classification_of_tumor	not reported
gdc__diagnoses__days_to_birth	-19214.0
gdc__diagnoses__days_to_death	627.0
gdc__diagnoses__days_to_last_follow_up	357.0
gdc__diagnoses__diagnosis_id	5302581d-379b-56a2-8e1e-25551e2bdf0a
gdc__diagnoses__last_known_disease_status	not reported
gdc__diagnoses__morphology	8170/3
gdc__diagnoses__primary_diagnosis	Hepatocellular carcinoma NOS
gdc__diagnoses__prior_malignancy	not reported
gdc__diagnoses__progression_or_recurrence	not reported
gdc__diagnoses__site_of_resection_or_biopsy	Liver
gdc__diagnoses__tissue_or_organ_of_origin	Liver
gdc__diagnoses__tumor_grade	not reported
gdc__diagnoses__tumor_stage	stage iiia
gdc__diagnoses__vital_status	dead
gdc__disease_type	Adenomas and Adenocarcinomas
gdc__experimental_strategy	miRNA-Seq
gdc__exposures__exposure_id	22ac9d24-8845-5f63-8788-d644a49e0778
gdc__exposures__height	178.0
gdc__file_id	449cdcd7-807d-4dcb-8bc7-eec3e53828f1
gdc__file_name	e64cb35d-cd67-41c0-8795-5b32c02d997a.mirbase21.mirnas.quantification.txt
gdc__file_size	50210
gdc__input_files__data_category	Raw Sequencing Data
gdc__input_files__data_format	BAM
gdc__input_files__data_type	Aligned Reads
gdc__input_files__experimental_strategy	miRNA-Seq
gdc__input_files__platform	Illumina
gdc__md5sum	52bc48010aea0c8281d290edcc6f133e
gdc__portions__is_ffpe	false
gdc__portions__portion_id	e6c67d3f-b0a4-4e17-a0d7-7af37ec473e5
gdc__portions__portion_number	11
gdc__portions__weight	30.0
gdc__primary_site	Liver and intrahepatic bile ducts
gdc__program__dbgap_accession_number	phs000178
gdc__program__name	TCGA
gdc__program__program_id	b80aa962-9650-5110-b3eb-bd087da808db
gdc__project__disease_type	Liver Hepatocellular Carcinoma
gdc__project__primary_site	Liver
gdc__project__project_id	TCGA-LIHC
gdc__project__releasable	false
gdc__project__released	true
gdc__samples__days_to_collection	106
gdc__samples__initial_weight	400.0
gdc__samples__oct_embedded	false
gdc__samples__pathology_report_uuid	CCEFF8C5-E949-4F3F-93DA-67ECF5503C1C
gdc__samples__sample_id	e6e1bf11-da29-4052-85a1-584401f0fa3d
gdc__samples__sample_type	Primary Tumor
gdc__samples__sample_type_id	01
gdc__slides__percent_lymphocyte_infiltration	0.0
gdc__slides__percent_monocyte_infiltration	0.0
gdc__slides__percent_necrosis	0.0
gdc__slides__percent_neutrophil_infiltration	0.0
gdc__slides__percent_normal_cells	0.0
gdc__slides__percent_stromal_cells	5.0
gdc__slides__percent_tumor_cells	95.0
gdc__slides__percent_tumor_nuclei	92.0
gdc__slides__section_location	TOP
gdc__slides__slide_id	373bc865-4bbb-48d2-9391-0c13e3df32ae
gdc__submitter_id	mirna_swap_dr11_411_MirnaExpressionbcbc7ac9-4254-4a7c-998d-7c305bffe8d1_profiling
gdc__tissue_source_site__bcr_id	NCH
gdc__tissue_source_site__code	EP
gdc__tissue_source_site__name	Christiana Healthcare
gdc__tissue_source_site__tissue_source_site_id	dbcb7cb8-b22c-5a78-9d41-b93e7eb08f05
gdc__treatments__treatment_id	851e1ec8-1170-5137-890f-13c36ec806b6
gdc__type	mirna_expression
gdc__updated_datetime	2018-09-08T13:43:34.032262+00:00
manually_curated__data_format	BED
manually_curated__download_date	2018-11-06T09:10:57.768+01:00
manually_curated__exp_data_bed_url	ftp://bioinformatics.iasi.cnr.it/opengdc/bed/tcga/tcga-lihc/mirna_expression_quantification/c1e285f1-c1ba-4412-b0d8-3f82e0ed4cd4-meq.bed
manually_curated__exp_metadata_url	ftp://bioinformatics.iasi.cnr.it/opengdc/bed/tcga/tcga-lihc/mirna_expression_quantification/c1e285f1-c1ba-4412-b0d8-3f82e0ed4cd4-meq.bed.meta
manually_curated__genome_built	GRCh38
manually_curated__local_file_size	129581
manually_curated__local_md5	93f28a4a38d57fa05db53584ee11eb15
manually_curated__opengdc_download_date	2018-10-16T17:12:55.000596+02:00
manually_curated__opengdc_file_md5	2940bce216f1d7d3712d6c74ca3c6380
manually_curated__opengdc_file_size	50209
manually_curated__opengdc_id	c1e285f1-c1ba-4412-b0d8-3f82e0ed4cd4-meq
manually_curated__origin_file_size	129581
manually_curated__origin_last_modified_date	Tue Oct 16 17:36:00 CEST 2018
manually_curated__origin_md5	93f28a4a38d57fa05db53584ee11eb15
manually_curated__tissue_status	tumoral
